PharmaTher is focused on unlocking the pharmaceutical potential of ketamine, specifically through its proprietary product KETARX™. This product is being developed for various applications, including pain management, mental health treatment, neurological disorders, and life-threatening conditions. The company aims to commercialize KETARX™ by leveraging its unique properties and therapeutic benefits associated with ketamine.

In addition to its product development efforts, PharmaTher is strategically targeting regulatory incentives to facilitate expedited approvals for its therapies. The company is utilizing pathways such as the FDA's Abbreviated New Drug Application (ANDA) and the 505(b)(2) regulatory pathway, along with pursuing orphan drug status, fast track designation, and breakthrough therapy designation. These strategies are designed to enhance the likelihood of successful and timely market entry for its innovative treatments.

Canada

PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) is a clinical-stage psychedelics biotech company focused on the research, development and commercialization of novel uses, formulations and delivery methods of psychedelics to treat mental illness, neurological and pain disorders.

Skulpt Health

Company Details